Attorney Docket No. 24852-513 (formerly 24852-501 CIP4)

Express Mail Label No.: EV942369198US Date of Deposit: December 20, 2007

## **AMENDMENT**

## Amendments to the Claims:

Please amend the claims as follows, without prejudice:

## In the Claims:

1. (Currently Amended) A method of treating <u>acute</u> leukemia in a subject, said method comprising the step of orally administering to the subject a total daily dose of 400 mg once daily of a pharmaceutical composition comprising suberoylanilide hydroxamic acid (SAHA) represented by the structure:

or a pharmaceutically acceptable salt or hydrate thereof, and a pharmaceutically acceptable carrier or diluent, wherein administration of SAHA or a pharmaceutically acceptable salt or hydrate thereof is <u>at a dose of 400 mg once daily</u>, and effective to treat <u>acute</u> leukemia in said subject.

## 2.-11. (Cancelled)

- 12. (Previously Presented) The method of claim 1, wherein said composition is contained within a gelatin capsule.
- 13. (Original) The method of claim 12, wherein said carrier or diluent is microcrystalline cellulose.
- 14. (Previously Presented) The method of claim 1, said composition further comprising sodium croscarmellose as a disintegrating agent.
- 15. (Previously Presented) The method of claim 1, said composition further comprising magnesium stearate as a lubricant.

Attorney Docket No. 24852-513 (formerly 24852-501 CIP4)

Express Mail Label No.: EV942369198US Date of Deposit: December 20, 2007

16-156. (Cancelled)

157. (Currently Amended) The method of any one of claims 1, 2, 3 and 12-15 and 179, wherein SAHA is the active ingredient in said <u>pharmaceutical</u> composition.

158.-178. (Cancelled).

179. (New) The method of claim 1, wherein the administration is on a continuous schedule.